Precigen, Inc.
PGENPrecigen, Inc.
NASDAQ
Healthcare
Biotechnology
$3.94
+0.01(0.1%)
52W $1.17 – $5.21
AI-generated
Precigen, Inc.
Revenue breakdown: Product And Service (33.6%), Service Exemplar (23.5%), Service (23.5%).
$1.2BMkt Cap
$6MRev TTM
-$250MNI TTM
-3.9xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 24, 2026Precigen, Inc. (PGEN) reported FY2025 total revenues of $9.7M, a 147% YoY increase from $3.9M in FY2024, driven by initial Papzimeos product sales of $4.0M post-FDA approval in August 2025, service revenues of $3.9M from Exemplar, and $1.8M collaboration revenue from terminated PTC deal. Operating expenses fell 14% YoY to $120.2M, reflecting pipeline prioritization pausing UltraCAR-T trials and ActoBio shutdown,...
Fundamentals
How The Business Makes Money
Revenue by Segment
Product And Service33.6%($18M)
Service Exemplar23.5%($13M)
Service23.5%($13M)
Product9.7%($5M)
Papzimeos6.3%($3M)
Product Exemplar3.4%($2M)
Revenue by Geography
Non Us100%($241.0K)
Analyst View
Company Profile
CIK0001356090
ISINUS74017N1054
CUSIP74017N105
Phone301 556 9900
Address20374 Seneca Meadows Parkway, Germantown, MD, 20876, US
SEC EDGAR